Selling the platform and San Francisco investment meetings
All about funding and building value............
Electrome's CMO provides more details on LymeCure
Nevena ZubcevikNevena Zubcevik
Co-founder and Chief Medical Officer at Electrome Corp
• 20 hours ago • Visible to anyone on or off LinkedIn
"We’re excited to share what we’ve been building in Lyme disease.
We’ve officially launched the LymeCure research study at Tulane, in collaboration with Monica Embers, PhD, with experimental work underway since November. Our approach is a bioelectric therapy designed to arrest spirochete flagellar motion directly, without relying on vascular delivery, without triggering a Herxheimer reaction, and without harming eukaryotic cells.
I’ve been inspired for years by the early work of Royal Raymond Rife, and we are now rigorously translating the concept of frequency-based biology into modern biophysics and engineering. Our team is extraordinary, and this platform has implications well beyond Lyme. Bartonella is next.
Our patent-pending, full-body treatment device is moving rapidly from bench to bedside, with plans to pursue the FDA’s Breakthrough Device pathway. The goal is to make this therapy available on an accelerated timeline while meeting the highest scientific and regulatory standards. (Fast track)
As a frontline physician caring for patients with Lyme disease and complex infections every day, I can say this with genuine optimism: we are entering a new chapter. The possibility of truly changing the trajectory of Lyme disease is now within reach.
I’ll be in San Francisco for investor meetings at the J.P. Morgan Healthcare Conference next week; happy to grab coffee if you’re around.
Ken Mayer Tulane University Electrome Corp Wanni Davis PhD MBA Fred Crawford Nigel Timothy (BIEL investor)
All about funding and building value............
Electrome's CMO provides more details on LymeCure
Nevena ZubcevikNevena Zubcevik
Co-founder and Chief Medical Officer at Electrome Corp
• 20 hours ago • Visible to anyone on or off LinkedIn
"We’re excited to share what we’ve been building in Lyme disease.
We’ve officially launched the LymeCure research study at Tulane, in collaboration with Monica Embers, PhD, with experimental work underway since November. Our approach is a bioelectric therapy designed to arrest spirochete flagellar motion directly, without relying on vascular delivery, without triggering a Herxheimer reaction, and without harming eukaryotic cells.
I’ve been inspired for years by the early work of Royal Raymond Rife, and we are now rigorously translating the concept of frequency-based biology into modern biophysics and engineering. Our team is extraordinary, and this platform has implications well beyond Lyme. Bartonella is next.
Our patent-pending, full-body treatment device is moving rapidly from bench to bedside, with plans to pursue the FDA’s Breakthrough Device pathway. The goal is to make this therapy available on an accelerated timeline while meeting the highest scientific and regulatory standards. (Fast track)
As a frontline physician caring for patients with Lyme disease and complex infections every day, I can say this with genuine optimism: we are entering a new chapter. The possibility of truly changing the trajectory of Lyme disease is now within reach.
I’ll be in San Francisco for investor meetings at the J.P. Morgan Healthcare Conference next week; happy to grab coffee if you’re around.
Ken Mayer Tulane University Electrome Corp Wanni Davis PhD MBA Fred Crawford Nigel Timothy (BIEL investor)
1
